
Jann Arends

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5164218/publications.pdf Version: 2024-02-01



IANN ADENDS

#	Article	IF	CITATIONS
1	ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition, 2017, 36, 11-48.	2.3	1,855
2	ESPEN expert group recommendations for action against cancer-related malnutrition. Clinical Nutrition, 2017, 36, 1187-1196.	2.3	758
3	Understanding the mechanisms and treatment options in cancer cachexia. Nature Reviews Clinical Oncology, 2013, 10, 90-99.	12.5	729
4	ESPEN guidelines on chronic intestinal failure in adults. Clinical Nutrition, 2016, 35, 247-307.	2.3	554
5	ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clinical Nutrition, 2015, 34, 171-180.	2.3	473
6	ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition, 2021, 40, 2898-2913.	2.3	472
7	Cancer cachexia: Diagnosis, assessment, and treatment. Critical Reviews in Oncology/Hematology, 2018, 127, 91-104.	2.0	140
8	Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids in Health and Disease, 2007, 6, 17.	1.2	130
9	Clinical classification of adult patients with chronic intestinal failure due to benign disease: An international multicenter cross-sectional survey. Clinical Nutrition, 2018, 37, 728-738.	2.3	107
10	Clinical approach to the management of Intestinal Failure Associated Liver Disease (IFALD) in adults: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN. Clinical Nutrition, 2018, 37, 1794-1797.	2.3	77
11	ESPEN practical guideline: Clinical nutrition in chronic intestinal failure. Clinical Nutrition, 2021, 40, 5196-5220.	2.3	74
12	From guidelines to clinical practice: a roadmap for oncologists for nutrition therapy for cancer patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988008.	1.4	68
13	Marine phospholipids—a promising new dietary approach to tumor-associated weight loss. Supportive Care in Cancer, 2010, 18, 159-170.	1.0	55
14	Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study. Oncology Research and Treatment, 2007, 30, 629-635.	0.8	33
15	Home parenteral nutrition provision modalities for chronic intestinal failure in adult patients: An international survey. Clinical Nutrition, 2020, 39, 585-591.	2.3	31
16	The importance of protein sources to support muscle anabolism in cancer: An expert group opinion. Clinical Nutrition, 2022, 41, 192-201.	2.3	30
17	Quality of care for cancer patients on home parenteral nutrition: development of key interventions and outcome indicators using a two-round Delphi approach. Supportive Care in Cancer, 2013, 21, 1373-1381.	1.0	23
18	Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Supportive Care in Cancer, 2020, 28, 979-1010.	1.0	22

JANN ARENDS

#	Article	IF	CITATIONS
19	Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome: An international multicenter survey. Clinical Nutrition ESPEN, 2021, 45, 433-441.	0.5	21
20	Metabolism in cancer patients. Anticancer Research, 2010, 30, 1863-8.	0.5	20
21	Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. Journal of Geriatric Oncology, 2021, 12, 521-530.	0.5	12
22	A fishy conclusion regarding n-3 fatty acid supplementation in cancer patients. Clinical Nutrition, 2013, 32, 466-467.	2.3	11
23	How to feed patients with gastrointestinal mucositis. Current Opinion in Supportive and Palliative Care, 2018, 12, 168-173.	0.5	9
24	Vitamin D in Oncology. Research in Complementary Medicine, 2011, 18, 2-2.	2.2	7
25	Supportive Care: Low Cost, High Value. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 240-250.	1.8	6
26	To Live or Not to Live. Journal of Parenteral and Enteral Nutrition, 2010, 34, 450-451.	1.3	5
27	Palliative Treatment: Anticancer, Antisymptom, or End-of-Life Care?. Journal of Clinical Oncology, 2011, 29, 4591-4591.	0.8	3
28	COVID-19 in Patients with Cancer. Advances in Experimental Medicine and Biology, 2021, 1318, 315-331.	0.8	3
29	Energy and protein intake may have an impact on survival in patients with advanced cancer. Clinical Nutrition, 2022, 41, 266-267.	2.3	2
30	Comment on van den Berg et al. Journal of Parenteral and Enteral Nutrition, 2012, 36, 504-504.	1.3	1
31	Supplemental parenteral nutrition: decisions based on weak evidence. ESMO Open, 2020, 5, e000831.	2.0	1
32	Reply to Dr. Tisdale's letter. Clinical Nutrition, 2007, 26, 163.	2.3	0
33	Assessing Evidence and the Need for Highâ€Quality Research in Clinical Nutrition. Nutrition in Clinical Practice, 2019, 34, 477-477.	1.1	Ο
34	Multimodale Therapie bei Tumorkachexie. , 2017, , 80-87.		0
35	Ernärungstherapie bei Tumorkachexie. , 2017, , 88-101.		0
36	Ernärung bei Tumorpatienten: Unzureichend beachtet. , 0, , .		0